Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient

• US 20040258749A1
• Filed: 04/08/2004
• Published: 12/23/2004
• Est. Priority Date: 10/09/2001
• Status: Active Grant

• Current Assignee: Dirk Pamperin, Jan Ploen, Michael Heschel, Peter Guldner, Steffen Scheithauser, Thomas Gramatte, Wolfgang Wehner
• Original Assignee: Dirk Pamperin, Jan Ploen, Michael Heschel, Peter Guldner, Steffen Scheithauser, Thomas Gramatte, Wolfgang Wehner
• Inventors: Wehner, Wolfgang, Guldner, Peter, Heschel, Michael, Pamperin, Dirk, Gramatte, Thomas, Ploen, Jan, Scheithauser, Steffen
• Granted Patent: US 7,943,176 B2
• Time in Patent Office: Days
• US Class Current: 424/464
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61P 13/06 Anti-spasmodics
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps

Abstract

By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pK_a value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.

Claims

1-10. -10. (Cancelled).

11. A pharmaceutical composition for oral administration having prolonged release of the active agent, containing propiverine and/or one or more pharmaceutically acceptable salts thereof, the composition having the following in vitro release, measured in 750 ml of 0.1 N hydrochloric acid during the first hour and subsequently measured in 750 ml USP buffer at pH=5.8 using a Ph. Eur. Basket method at 100 rpm and 37°

C.;